Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Cancer treatment stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00
Nov 15, 2026

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.

Nov 15, 2026·2 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00
Nov 6, 2026

Pope Leo XIV begins 12-day South America tour weeks after lung cancer surgery

Pope Leo XIV departed for a 12-day trip through Uruguay, Argentina, and Peru on Friday, his first major foreign visit as pope and a return to the continent where he spent two decades as a missionary, coming just three weeks after undergoing lung cancer surgery.

Nov 6, 2026·6 sources
00
Nov 3, 2026

Amgen raises 2026 revenue forecast on strong cholesterol and cancer drug sales

Amgen raised its sales and profit forecast for the third time in 2026 after third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra and Uplizna.

Nov 3, 2026·2 sources
00

Pfizer raises 2026 outlook on strong demand for non-Covid drugs

Pfizer raised its full-year profit and revenue outlook after third-quarter results beat estimates, driven by growing demand for newly launched and acquired medicines as Covid product sales decline.

Nov 3, 2026·4 sources
00

Bayer raises 2026 profit outlook on strong pharmaceutical demand

Bayer AG raised its annual profit outlook after better-than-expected third-quarter performance driven by demand for newer drugs in its pharmaceuticals business.

Nov 3, 2026·2 sources
00
Oct 30, 2026

Mayo Clinic study finds checkpoint immunotherapy reshapes immune environment in melanoma-affected lymph nodes

A new Mayo Clinic study reveals that checkpoint immunotherapy may reorganize the immune environment within lymph nodes after melanoma has spread to them. The research demonstrates how the treatment restructures immune cell interactions in affected lymph nodes.

Oct 30, 2026·2 sources
00

Fox Chase Cancer Center identifies ANO6 protein as target to slow pancreatic cancer growth

Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.

Oct 30, 2026·2 sources
00

Stanford Medicine study links mental health disorders to higher cancer mortality

A Stanford Medicine study found that cancer survivors diagnosed with mental health disorders two to five years after their cancer diagnosis had a 119% higher rate of death from cancer compared to patients without documented mental disorders during the same period. The research highlights a previously overlooked period of vulnerability for cancer survivors.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Northwestern Medicine develops liquid biopsy blood test for small cell lung cancer

Northwestern Medicine scientists have demonstrated a novel liquid biopsy technique that can measure cancer burden and reveal molecular characteristics of small cell lung cancer, according to a study published in the Journal of Clinical Investigation. The approach could eventually allow for better tracking and monitoring of this aggressive cancer type.

Oct 29, 2026·2 sources
00

Roswell Park researchers identify timing window for immunotherapy in prostate cancer treatment

Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.

Oct 29, 2026·1 source
00

KAIST researchers develop GB2Ab antibody to treat cancer cachexia in mice

A research team at KAIST has developed GB2Ab, a therapeutic antibody candidate that blocks signals responsible for appetite suppression, weight loss, and muscle wasting in cancer cachexia. The antibody successfully reversed weight and muscle loss in mouse models.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Genmab's petosemtamab cuts death risk by half in head and neck cancer trial

Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.

Oct 28, 2026·3 sources
00
Oct 27, 2026

Asciminib shows stronger suppression of leukemia protein than existing treatments in new study

A study led by Adelaide University and SAHMRI provides the first direct evidence that asciminib, a targeted therapy for chronic myeloid leukemia, can rapidly and consistently suppress the cancer-driving protein within one week, offering a more effective and better-tolerated treatment option for CML patients.

Oct 27, 2026·2 sources
00

Bevacizumab and pazopanib combination extends survival in kidney cancer trial

A phase 1/2 trial led by Roswell Park Comprehensive Cancer Center found that combining bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with metastatic clear-cell renal cell carcinoma, the most common type of kidney cancer. The study established a safe dosing regimen and demonstrated promising antitumor activity in treatment-naive patients.

Oct 27, 2026·2 sources
00

BYU researchers develop MOTO-CAR macrophage therapy to target solid tumors in preclinical study

Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.

Oct 27, 2026·2 sources
00

GradientScreen lab-on-chip technology predicts childhood leukemia treatment response

Researchers have developed a gradient-driven microfluidic lab-on-chip platform called GradientScreen that can predict which drug combinations will be most effective for treating pediatric acute lymphoblastic leukemia. The technology screens ratiometric drug combinations to enable precision oncology approaches for the disease, which affects more than 3,500 children annually in the U.S.

Oct 27, 2026·3 sources
00
Oct 26, 2026

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00

Fewer US men diagnosed with low-risk prostate cancer as surveillance replaces treatment

An analysis published in CANCER reveals a broad shift away from overtreatment of low-risk prostate cancer in the United States, with more men choosing surveillance over immediate treatment in response to concerns about overdiagnosis and overtreatment.

Oct 26, 2026·1 source
00
Oct 25, 2026

AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial

AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.

Oct 25, 2026·2 sources
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00

Nearly 30% of advanced melanoma patients achieve complete tumor disappearance with lifileucel TIL therapy plus pembrolizumab

Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.

Oct 24, 2026·1 source
00
Oct 23, 2026

Real-world study confirms Lu-PSMA-617 benefits for metastatic prostate cancer patients

Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.

Oct 23, 2026·4 sources
00

Bristol Myers Squibb and SystImmune breast cancer drug reduces disease progression risk by 59% in phase 3 trial

Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.

Oct 23, 2026·4 sources
00

Novartis breast cancer drug Kisqali cuts death risk by 19% after six years in early-stage trial

Novartis reported that its drug Kisqali helped extend survival for women with high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years in trial data.

Oct 23, 2026·2 sources
00

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 2026·2 sources
00

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00

Johnson & Johnson prostate cancer drug JNJ-6143 shows tumor shrinkage in early-stage trial

Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.

Oct 23, 2026·4 sources
00

Diagnostic test could help doctors refine prostate cancer treatment with abiraterone

A novel diagnostic test could enable doctors to identify which prostate cancer patients would benefit from more intensive treatment with drugs like abiraterone, while sparing others from unnecessary side effects. The test aims to address the challenge of tailoring treatment for prostate cancer, which affects over 1 million men worldwide and behaves differently in each patient.

Oct 23, 2026·5 sources
00

Researchers discover how chronic lymphocytic leukemia cells evade treatment by switching survival signals

A new study published in Blood Journal reveals that chronic lymphocytic leukemia (CLL) cells can switch between different survival signals to evade treatment, helping explain why therapies work for some patients but develop resistance in others. The research identifies how cancer cells alternate between low and high basal signaling states through TLR9 activation.

Oct 23, 2026·3 sources
00

RCSI study identifies new treatment targets for most common type of colorectal cancer

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London has identified potential new treatment approaches for microsatellite-stable colorectal cancer, the most common type in Ireland. The study provides a roadmap for repurposing existing drugs to treat this cancer subtype.

Oct 23, 2026·3 sources
00

New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer

A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.

Oct 23, 2026·4 sources
00
Oct 22, 2026

Molecular glue RPT04402 stabilizes PP2A protein to inhibit lung and uterine cancer development

Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.

Oct 22, 2026·3 sources
00

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00

UCLA researchers develop MAESTRO AI platform to identify cancer drug combinations

UCLA investigators have created MAESTRO, an artificial intelligence platform that uses large language models to analyze scientific knowledge and identify promising drug combinations to overcome treatment resistance in cancer. The platform was described in the journal Advanced Science.

Oct 22, 2026·2 sources
00

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

A University of Pittsburgh study published in JAMA Otolaryngology–Head & Neck Surgery found that head and neck cancer patients who participated in multidisciplinary survivorship clinics earlier experienced better survival rates and lower cancer recurrence compared to those who began survivorship care later.

Oct 22, 2026·2 sources
00
Oct 21, 2026

OpenAI and Peter Thiel's Founders Fund invest in Coherence Neuro's cancer-detecting brain implant

Coherence Neuro has raised $45 million in funding from OpenAI's venture capital arm and Founders Fund to develop a brain implant designed to detect and treat cancer. The coin-sized device monitors tumor activity through neural signals.

Oct 21, 2026·2 sources
00
Oct 20, 2026

Dana-Farber and Beth Israel begin construction of $1.68 billion cancer hospital

Dana-Farber Cancer Institute and Beth Israel Lahey Health are starting construction on a $1.68 billion cancer hospital in Boston, marking a new phase in their competition with Mass General Brigham.

Oct 20, 2026·2 sources
00
Oct 19, 2026

FDA grants accelerated approval to dostarlimab for dMMR rectal cancer

The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.

Oct 19, 2026·4 sources
00
Oct 15, 2026

Armed Cell Therapeutics acquires Galapagos CAR-T therapies from Lakefront Biotherapeutics

Armed Cell Therapeutics, a Belgian startup chaired by former Galapagos CEO Paul Stoffels, has acquired the CAR-T cell therapy assets that Lakefront Biotherapeutics (formerly Galapagos) divested during its strategic overhaul. The deal allows Stoffels to continue developing the cancer cell therapies he had championed during his tenure at Galapagos.

Oct 15, 2026·3 sources
00
Oct 7, 2026

FDA approves Pfizer's TUKYSA as first-line maintenance treatment for HER2+ metastatic breast cancer

The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.

Oct 7, 2026·4 sources
00
Sep 25, 2026

NHS begins using rapid brain tumour test that cuts diagnosis time from weeks to hours

The NHS has started using a new rapid genetic test that can diagnose brain tumours in approximately two hours while patients are still on the operating table, compared to the previous wait of up to eight weeks. The test uses DNA analysis to identify which type of tumour a patient has, allowing doctors to begin treatment much sooner.

Sep 25, 2026·5 sources
00
Sep 23, 2026

FDA approves Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 alterations

The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.

Sep 23, 2026·2 sources
00
Sep 21, 2026

Imlunestrant combination approved for ESR1-mutated breast cancer

Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.

Sep 21, 2026·1 source
00
Sep 17, 2026

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00
Sep 16, 2026

England approves breast cancer drug Enhertu after UK-US pharma deal

England's NHS will provide AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for aggressive breast cancer after the drug was previously rejected twice. The approval follows an agreement reached with the companies.

Sep 16, 2026·3 sources
00
Sep 15, 2026

Harold Freeman, who helped remove barriers to cancer treatment, dies at 93

Harold Freeman, a pioneering physician who worked to eliminate barriers to cancer treatment and improve healthcare access for underserved communities, has died at age 93.

Sep 15, 2026·1 source
00

Atezolizumab fails primary endpoint in IMpower030 trial for resectable lung cancer

The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.

Sep 15, 2026·1 source
00
Sep 14, 2026

FDA approves photodynamic therapy for superficial basal cell carcinoma

The FDA has approved photodynamic therapy as a treatment option for superficial basal cell carcinoma, the most common form of skin cancer. The approach is particularly suited for cosmetically sensitive areas of the body.

Sep 14, 2026·1 source
00
Sep 13, 2026

Multimodal AI model outperforms established biomarkers for immunotherapy in lung cancer

A large international real-world study found that a multimodal explainable AI decision support tool outperformed established biomarkers for predicting immunotherapy outcomes in non-small cell lung cancer and improved physician decision-making.

Sep 13, 2026·2 sources
00
Sep 12, 2026

FDA expands approval for sevabertinib to frontline treatment of HER2-mutant advanced NSCLC

The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.

Sep 12, 2026·1 source
00
Sep 3, 2026

AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma

AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.

Sep 3, 2026·3 sources
00
Sep 1, 2026

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00
Aug 28, 2026

BioNTech halts colorectal cancer vaccine trial after safety review finds treatment unlikely to extend survival

BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.

Aug 28, 2026·2 sources
00

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00
Aug 15, 2026

Innovent Biologics doses first patient in phase 3 trial of IBI363 for advanced colorectal cancer

Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.

Aug 15, 2026·1 source
00
Aug 14, 2026

FDA approves Bristol Myers Squibb's Zenbexus, first CELMoD drug for multiple myeloma

The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.

Aug 14, 2026·4 sources
00
Aug 6, 2026

FDA approves Replimune's melanoma drug after two prior rejections

The FDA granted accelerated approval to Replimune's TUDRIQEVTM (vusolimogene oderparepvec-wtpg) for melanoma treatment, reversing two earlier rejections following support from an advisory panel. The approval marks a significant turnaround for the biotech company after a tumultuous regulatory process.

Aug 6, 2026·3 sources
00
Aug 2, 2026

FDA expands Pluvicto approval for earlier-stage metastatic prostate cancer treatment

The FDA has approved Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with hormone therapy for patients with PSMA-positive metastatic prostate cancer who are still hormone-sensitive, nearly doubling the eligible patient population from its previous indication for hormone-resistant cases.

Aug 2, 2026·8 sources
00
Jul 28, 2026

FDA staff reiterate concerns about Replimune skin cancer treatment ahead of advisory meeting

FDA staff raised ongoing concerns about Replimune's experimental skin cancer therapy in briefing documents released before an advisory committee meeting, questioning the treatment's efficacy data.

Jul 28, 2026·1 source
00
Jul 27, 2026

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00
Jul 23, 2026

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.

Jul 23, 2026·9 sources
00
Jul 15, 2026

Johnson & Johnson beats earnings estimates on strength of Tremfya and Darzalex

Johnson & Johnson exceeded Wall Street estimates for second-quarter sales and profit, driven by strong demand for immunology drug Tremfya and cancer treatment Darzalex, offsetting erosion in other product lines.

Jul 15, 2026·1 source
00
Jul 8, 2026

AstraZeneca and Daiichi Sankyo Near UK Pricing Agreement for Breast Cancer Drug Enhertu

AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer treatment Enhertu, which could provide access to women in England and Wales with HER2-low breast cancer.

Jul 8, 2026·2 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00
Jun 30, 2026

FDA Approves Orca Bio's TREGZI as First Precision-Engineered Cell Therapy for Blood Cancer Transplants

The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.

Jun 30, 2026·7 sources
00
Jun 29, 2026

AbbVie and Genmab's Epkinly Combination Meets Primary Endpoint in Phase 3 Trial for Relapsed/Refractory DLBCL

The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.

Jun 29, 2026·6 sources
00
Jun 24, 2026

FDA approves Trodelvy for first-line triple-negative breast cancer

The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.

Jun 24, 2026·3 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
May 30, 2026

Incyte Blood Cancer Drug Combo Reduces Disease Progression Risk in Aggressive Lymphoma

Incyte's Monjuvi as part of a multi-drug regimen for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death, though with a high side-effect rate.

May 30, 2026·1 source
00

Multi-fraction stereotactic radiation improves local control for large brain metastases in phase 3 trial

The first randomized phase 3 trial comparing radiation schedules found that delivering stereotactic radiation over three to five sessions after surgery significantly improved local control and reduced cancer recurrence at the surgical site for patients with large, resected brain metastases compared with single-fraction treatment.

May 30, 2026·3 sources
00
May 14, 2026

CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines secured $122 million in funding to advance its CAR-T therapy candidates through human trials, alongside a company rebrand and expanded pipeline.

May 14, 2026·1 source
00
May 4, 2026

FDA Rejects Promising Melanoma Drug RP1 Twice, Raising Concerns About Drug Approval Process

The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.

May 4, 2026·1 source
00
Apr 17, 2026

Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial

Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.

Apr 17, 2026·1 source
00
Dec 3, 2025

AI Systems Advance Treatment and Care for Blood Cancer Patients

Researchers have developed artificial intelligence tools to support clinical decision-making in hematologic malignancies, including HemaGuide from German Cancer Research Center for treatment recommendations and AI applications in palliative oncology for symptom management and prognostication.

Dec 3, 2025·2 sources
00
Dec 2, 2025

Biofrontera submits FDA application for Ameluz skin cancer treatment

Biofrontera Inc. filed a supplemental New Drug Application with the FDA on November 28, 2025, seeking approval to treat superficial basal cell carcinoma with Ameluz photodynamic therapy. This represents the first Phase 3 PDT study in sBCC patients conducted in the United States.

Dec 2, 2025·2 sources
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

People involved

Yamandú OrsiPeter ThielWilliam Ruto

Subtopics

Cancer & Oncology56Drug Policy, Pricing & Approval37Clinical trials30Drug Approval and Clinical Trials30Oncology28Cancer treatment breakthroughs22Cancer research19Cancer and Cancer Treatment18Cancer immunotherapy12Drug development12FDA drug approval12Targeted cancer therapy12Immunotherapy11Pharma11Precision medicine11Cancer Types9Pharmaceutical Industry8Biomedical research7Cancer7Cancer Treatment & Therapies7Clinical Trial Design & Evaluation5AI in healthcare4Cancer diagnosis4Clinical trial endpoints4

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories